ArticleFrontiers in immunology2022
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 64 citations in OpenAlex.
- Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026Review
- From barrier to trigger: leveraging tumor hypoxia for precise control of CAR-T cell activity.Molecular biology reports · 2026Review
- Progress in the development of cytokine armoured CAR T cells.Nature reviews. Immunology · 2026Review
- A pilot study combining primary busulfan-based haploidentical stem cell transplantation with GD2 antibody to treat high-risk neuroblastoma.Bone marrow transplantation · 2026Article
- Targeting GD2 with CAR-T Cell Therapy in Neuroblastoma: Updates, Challenges, and Future Perspectives.Current oncology reports · 2026Review
- Article
- The Evolving Landscape of CAR T-Cell Therapy in Autoimmune Diseases: A State-of-the-Art Review (2025).Clinical reviews in allergy & immunology · 2026Review
- CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.Cancer metastasis reviews · 2026Review
- How can we balance risk and benefit of interleukin-18 armored T cell therapies?Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Advancing breast cancer treatment through dual targeting CAR T cell therapy.Discover oncology · 2025Review
- Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System.Immunity, inflammation and disease · 2025Review
- LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies.HLA · 2025Article
- Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications.Medical oncology (Northwood, London, England) · 2025Review
- EF1α, rather than CMV promoter, is suitable for luciferase tag expression in target cells forMolecular therapy. Methods & clinical development · 2025Article
- Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer.Clinical and experimental medicine · 2025Review
- Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy.Experimental hematology & oncology · 2025Review
- Targets for CAR Therapy in Multiple Myeloma.International journal of molecular sciences · 2025Review
- Strategies for Altering Delivery Technologies to Optimize CAR Therapy.International journal of molecular sciences · 2025Review
- Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Effectors of the Future: Universal Chimeric Antigen Receptor.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Wolfgang GlienkeATMP-GMP Development Unit, Institute of Cellular Therapeutics, Integrated Research and Treatment Center for Transplantation, Hannover Medical School, Hannover, Germany.
Anna Christina DragonInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Katharina ZimmermannDivision of Hematology/Oncology, Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Alexandra Martyniszyn-EibenATMP-GMP Development Unit, Institute of Cellular Therapeutics, Integrated Research and Treatment Center for Transplantation, Hannover Medical School, Hannover, Germany.
Mira MertensATMP-GMP Development Unit, Institute of Cellular Therapeutics, Integrated Research and Treatment Center for Transplantation, Hannover Medical School, Hannover, Germany.
Hinrich AbkenLeibniz Institute for Immunotherapy, Div Genetic Immunotherapy, Regensburg, Germany.
Claudia RossigDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
Bianca AltvaterDepartment of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
Krasimira AleksandrovaCellular Therapy Center, Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany.
Lubomir ArsenievCellular Therapy Center, Institute of Cellular Therapeutics, Hannover Medical School, Hannover, Germany.
Christina KlothDivision of Hematology/Oncology, Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Andriana StamopoulouDivision of Hematology/Oncology, Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Thomas MoritzDivision of Hematology/Oncology, Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Holger N LodeDepartment of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
Nikolai SiebertDepartment of Pediatric Hematology and Oncology, University Medicine Greifswald, Greifswald, Germany.
Rainer BlasczykInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Lilia GoudevaInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Axel SchambachDivision of Hematology/Oncology, Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Ulrike KöhlATMP-GMP Development Unit, Institute of Cellular Therapeutics, Integrated Research and Treatment Center for Transplantation, Hannover Medical School, Hannover, Germany.
Britta Eiz-VesperInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Ruth EsserATMP-GMP Development Unit, Institute of Cellular Therapeutics, Integrated Research and Treatment Center for Transplantation, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DEUniversitätsmedizin Greifswald · DEUniversity Hospital Münster · DEHarvard University · USLeibniz Institute for ImmunotherapyLeipzig University · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus, approaches using 4
Indexed as
CD8-Positive T-LymphocytesInterleukin-18CytokinesKiller Cells, NaturalMotor VehiclesCytokinesInterleukin-184th generation CARGD2-CARGMPIL-18ProdigyTRUCK
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.